Poster Walk

ESH eLearning, Faculty / Presenters, 312770

The long-term impact of TFR on economics

ESH eLearning, Francois-Xavier Mahon, 285152

Awardee 2019

ESH eLearning, Carolina Pavlovsky, 285150

Homeostatic interferon priming in haematopoietic stem cells

ESH eLearning, Marieke ESSERS, 285149

Curing CML: To be, or not to be, that is the question

ESH eLearning, Francois-Xavier Mahon, 285151

“Efficacy and Safety of Bosutinib by Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results From the Phase 4 BYOND Study

ESH eLearning, Tim Brümmendorf, 285155

Keynote presentation : 20 years of TKI therapy in CML: What have we learned?

ESH eLearning, Charles SCHIFFER, 285148

Adaptive Oncogenesis

ESH eLearning, James DE GREGORI, 285147

Late relapses after TKI-discontinuation are not uncommon and exhibit different kinetics as compared to early relapses - a preliminary report from after−SKI

ESH eLearning, Johan Richter, 285146

Novel Ways To Activate And Target NK Cells With Specificity to Leukemia: From Individual To Off-The-Shelf Products

ESH eLearning, Jeffrey Miller, 285154

Loss of Abelson interactor-1 is linked to inflammatory hematopoiesis and accelerated aging of hematopoietic system

ESH eLearning, Max Petersen, 285153

NF-kappa B-dependent proteasome activation as a mechanism of resistance to imatinib

ESH eLearning, Anna Eiring, 285145

Keynote presentation : Deciphering the molecular and functional complexity of pre-leukemic and leukemic stem cells in CML

ESH eLearning, Peter VALENT, 285144

Individual response of CML patients to TKI dose reduction can reliably identify patients with high risk of molecular relapse after treatment cessation

ESH eLearning, Ingo Roeder, 285143

The dysregulated CML stem/progenitor cell secretome alters the polarisation and function of Philadelphia chromosome negative bone marrow niche macrophages

ESH eLearning, Amy DAWSON, 285142

Les Défis des Maladies du Globule Rouge

ESH eLearning, Yves Beuzard, 286514

Panel Discussion on the ESH John Goldman International Research Award on Treatment Free Remission

ESH eLearning, Faculty / Presenters, 286464

Mechanisms of B-cell development with relevance to lymphomagenesis

ESH eLearning, Ulf Klein, 286465

Signaling components in lymphoma

ESH eLearning, Thomas OELLERICH, 286466

Pathogenesis of Hodgkin lymphoma

ESH eLearning, Christian STEIDL, 286467

Epigenetics in lymphoma

ESH eLearning, Ari Melnick, 286468

Molecular mechanisms of B-cell neoplasms

ESH eLearning, Thomas OELLERICH, 283465

Evolution of the genomic landscape in CLL

ESH eLearning, Dan Landau, 283466

Insights from single cell or proteome analysis in lymphoma

ESH eLearning, Ash ALIZADEH, 283467

Transformation and genomics in follicular lymphoma

ESH eLearning, Jude FITZGIBBON, 286469

Novel mouse models of aggressive lymphoma reveal distinct molecular vulnerabilities

ESH eLearning, Christian REINHARDT, 286470

The role of the microenvironment in lymphoma

ESH eLearning, Karin Tarte, 286471

Modulation of the tumour microenvironment in CLL

ESH eLearning, Silvia Deaglio, 286472

Targeting of kinases to modify the lymphoma microenvironment

ESH eLearning, Hien Nguyen, 286473

Metabolic gatekeepers in B-lymphoid malignancies

ESH eLearning, Markus MUSCHEN, 286474

CARs, TRUCKs and beyond : novel strategies and constructs

ESH eLearning, Hinrich ABKEN, 286475

CAR-T cell update in DLBCL

ESH eLearning, Stephen J. SCHUSTER, 286476

Longterm follow-up of CD19 CAR therapy in acute lymphoblastic leukaemia

ESH eLearning, Jae Park, 286477

Targeting the signaling pathways of lymphoid malignancies

ESH eLearning, Andreas Strasser, 283472

Faculty panel discussion: What are the big discoveries in lymphoma pathogenesis over the last 5 years? PART 1: Genetics and precision medicine

ESH eLearning, Dr. A Melnick (moderator), Dr. R Dalla-Favera, Dr. J Fitzgibbon, Dr. E Campo & Dr. C Reinhardt, 283468

Faculty panel discussion: What are the big discoveries in lymphoma pathogenesis over the last 5 years? PART 2: Liquid biopsy

ESH eLearning, Dr. A Melnick (moderator), Dr. R Dalla-Favera, Dr. J Fitzgibbon, Dr. E Campo & Dr. C Reinhardt, 285231

Strategies to integrate genomics, novel agents and traditional approaches

ESH eLearning, Barbara Eichhorst, 283473

Faculty panel discussion: What are the big discoveries in lymphoma pathogenesis over the last 5 years? PART 3: Tumor microenvironment and AI

ESH eLearning, Dr. A Melnick (moderator), Dr. R Dalla-Favera, Dr. J Fitzgibbon, Dr. E Campo & Dr. C Reinhardt, 285233

Faculty panel discussion: What are the big discoveries in lymphoma pathogenesis over the last 5 years? PART 4: Epigenetics and targeted therapies

ESH eLearning, Dr. A Melnick (moderator), Dr. R Dalla-Favera, Dr. J Fitzgibbon, Dr. E Campo & Dr. C Reinhardt, 285235

Metabolic gatekeepers in B-lymphoid malignancies

ESH eLearning, Markus MUSCHEN, 283469

Faculty panel discussion: What is the contribution of the immune system in pathogenesis and therapy of lymphoma?

ESH eLearning, Dr. M Hallek (moderator), Dr. S Schuster and Dr. K Tarte, 283470

Mechanisms of resistance against CAR-T cell therapy

ESH eLearning, Andrei THOMAS-TIKHONENKO, 286478

Preparatory regimen for efficient CAR-T cell therapy

ESH eLearning, David MALONEY, 286479

Mantle cell lymphoma

ESH eLearning, Simon RULE, 286480

CNS

ESH eLearning, Gerald Illerhaus, 286481

Waldenström macroglobulinemia

ESH eLearning, Christian Buske, 286482

Ph-like B-ALL

ESH eLearning, Sarah Tasian, 286483

Targeted therapy in hairy cell leukaemia

ESH eLearning, Brunangelo FALINI, 283474

How to ensure that breakthroughs will happen for NHL/CLL

ESH eLearning, Anas Younes, 283475

Preparatory regimen for efficient CAR-T cell therapy

ESH eLearning, David MALONEY, 283471

Faculty panel discussion: What are the optimal therapeutic strategies of the future for selected lymphoid malignancies?

ESH eLearning, Dr. L Sehn (moderator), Dr. C Buske and Dr. B Falini, 283476

Lymphoma xenografts: how to get back to the bench?

ESH eLearning, David Weinstock, 286484

Innovative, adaptive trial design for CLL

ESH eLearning, Andrew PETTITT, 286485

Placenta derived decidua stromal cells for severe acute GVHD and toxicity following allogeneic HSCT

ESH eLearning, Olle RINGDEN, 284339

Application of CAR technology to regulatory T cells

ESH eLearning, Megan LEVINGS, 284340

Is Tafasitamab an alternative to CAR-T?

ESH eLearning, Johannes DÜLL, 284341

IL-1R8, a checkpoint molecule in NK cell-mediated anti-tumoral and anti-viral activity

ESH eLearning, Cecilia Garlanda, 284336

Immunosuppressive activity of MSC: resolving the mechanism of action

ESH eLearning, Francesco DAZZI, 284337

Clinical trials with TCR engineered T cells

ESH eLearning, Aude CHAPUIS, 284338

Bispecific antibodies for acute myeloid leukaemia. Early results and challenges

ESH eLearning, John Godwin, 284335

ALL and DLBCL

ESH eLearning, Cameron TURTLE, 284329

Blocking co-stimulation as anti-myeloma immunotherapy

ESH eLearning, Kelvin LEE, 284330

CD44v6 CAR T cells for AML and MM

ESH eLearning, Fabio Ciceri, 284331

Modeling cytokine release syndrome: challenges of defining the undefinable

ESH eLearning, David BARRETT, 284332

Overcoming antigen escape in the setting of CAR T Cell immunotherapy

ESH eLearning, Michael JENSEN, 284333

Next Generation CAR T-cell for Therapy

ESH eLearning, Renier Brentjens, 284334

Indications for Allogeneic HSCT for Adult Acute Lymphoblastic Leukemia

ESH eLearning, Mark R. Litzow, 279753

Should MRD overcome baseline factors in risk assessment? Adult vs Paediatric opinions

ESH eLearning, Anthony Moorman, 279752

Antibody Conjugates in ALL

ESH eLearning, Hagop Kantarjian, 279751

Metabolism, disposition, and toxicity of ALL drugs

ESH eLearning, Mary V. Relling, 279750

JAK/STAT signaling in T-ALL

ESH eLearning, Pieter Van Vlierberghe, 279749

Targeting oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia

ESH eLearning, Jan Cools, 279748

The new taxonomy of B-ALL

ESH eLearning, Charles Mullighan, 279747

NO

ESH eLearning, Nelson LEUNG, 261677

YES

ESH eLearning, Bertrand Arnulf, 261663

Bispecific antibodies in the treatment of multiple myeloma

ESH eLearning, Hermann Einsele, 261669

Antibody based immune therapy

ESH eLearning, Niels W.C.J. van de Donk, 261689

Car-T cell in clinical practice

ESH eLearning, Hermann Einsele, 261668

Meta-analyses - how to interpret and to translate to clinical practice

ESH eLearning, Robert Hills, 261673

Is this multiple myeloma? A patient with high serum light chains and renal failure

ESH eLearning, Stefan Knop, 261676

A patient with proteasome inhibitors- and immunomodulatory drugs -refractory disease

ESH eLearning, Salomon Manier, 261679

A transplant-eligible patient with a non-aggressive relapse 24 months after autologous stem cell transplant followed by lenalidomide maintenance

ESH eLearning, Francesca Gay, 261671

A transplant- ineligible patient with partial response after 12 cycles of lenalidomide-dexamethasone - to continue, to limit, to change?

ESH eLearning, Inger Nijhof, 261684

A transplant-eligible patient with an aggressive relapse 12 months after autologous stem cell transplant - what to do now?

ESH eLearning, Paula Rodríguez-Otero, 261687

Smouldering disease - from definition to treatment

ESH eLearning, Salomon Manier, 261672

How to manage side effects

ESH eLearning, Inger Nijhof, 261683

Late relapse

ESH eLearning, Stefan Knop, 261681

First relapse in transplant eligible

ESH eLearning, Sagar Lonial, 261678

Waldenstrom Macroglobulinemia

ESH eLearning, Jorge Castillo, 261664

Monoclonal gammopathy of clinical significance

ESH eLearning, Angela Dispenzieri, 261667

Amyloidosis from diagnosis to treatment

ESH eLearning, Giovanni Palladini, 261680

Transplant non-eligible

ESH eLearning, Thierry Facon, 261670

Transplant eligible

ESH eLearning, Michele Cavo, 261665

First relapse in transplant non eligible

ESH eLearning, KARTHIK Ramasamy, 261686

Bone disease - personalized limited treatment

ESH eLearning, Evangelos Terpos, 261688

Bone disease - continuous treatment

ESH eLearning, Charlotte Pawlyn, 261685

Functional imaging characteristics of myeloma - promising now, predicting in the future?

ESH eLearning, Elena Zamagni, 261690

What is old - from biology of the disease to patient

ESH eLearning, Sonja Zweegman, 261691